James Lewis, MD
Ophthalmology · Elkins Park, PANPI 1225092315
Payments from drug & device makers
Across 117 payments — averaging $466.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ivantis, Inc$41K
- Rxsight Inc$7K
- Nidek Incorporated$4K
- Alcon$545
- Oyster Point Pharma, Inc.$239
- Bausch & Lomb Americas Inc.$220
- plus $1K from 20 others
What the payments were for
- Consulting fees$47,10586%
- Speaking & faculty fees$4,1178%
- Food & beverage$3,3336%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ivantis, Inc | 30 | $41,335 |
| Rxsight Inc | 1 | $7,080 |
| Nidek Incorporated | 2 | $4,117 |
| Alcon | 21 | $545 |
| Oyster Point Pharma, Inc. | 9 | $239 |
| Bausch & Lomb Americas Inc. | 9 | $220 |
| Dompe US, Inc. | 4 | $143 |
| Aerie Pharmaceuticals, Inc. | 1 | $141 |
| Kala Pharmaceuticals, Inc. | 6 | $109 |
| Sight Sciences, Inc. | 4 | $77 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $72 |
| Harrow Eye, LLC | 3 | $70 |
| NEW World Medical,inc. | 4 | $69 |
| Mallinckrodt Hospital Products Inc. | 2 | $48 |
| ANI Pharmaceuticals, Inc. | 2 | $44 |
| Eyevance Pharmaceuticals LLC | 2 | $36 |
| AbbVie | 2 | $34 |
| Tarsus Pharmaceuticals, Inc. | 1 | $31 |
| Biotissue Holdings Inc. | 2 | $30 |
| Rayner Intraocular Lenses Limited | 1 | $27 |
| Glaukos Corporation | 1 | $24 |
| Novartis | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $15 |
| Beaver-visitec International, Inc. | 1 | $13 |
| Iridex Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,574 in reported general payments places this provider in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SimbrinzaBrinzolamide/Brimonidine Tart | 181 | $49,198 |
| LumiganBimatoprost | 86 | $44,785 |
| MieboPerfluorohexyloctane/Pf | 53 | $42,266 |
| RhopressaNetarsudil Mesylate | 80 | $39,824 |
| Prednisolone Acetate | 1,157 | $34,312 |
| RestasisCyclosporine | 27 | $31,487 |
| RocklatanNetarsudil Mesylat/Latanoprost | 39 | $22,607 |
| XiidraLifitegrast | 11 | $20,368 |
| VyzultaLatanoprostene Bunod | 36 | $17,034 |
| Travoprost | 74 | $14,645 |
| Ketorolac Tromethamine | 984 | $11,640 |
| Cyclosporine | 21 | $10,795 |
| Alphagan PBrimonidine Tartrate | 34 | $10,493 |
| Latanoprost | 1,198 | $10,374 |
| TyrvayaVarenicline Tartrate | 15 | $9,526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $34 | $93,963160 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $220 | $79,668100 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $141 | $62,431119 claims |
| AlconSimbrinza | $545 | $49,198181 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $239 | $9,52615 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $109 | $5,92120 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $72 | $3,98320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Elkins Park
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
- Brandon AyresBala Cynwyd$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.